Literature DB >> 15981722

Percutaneous vertebroplasty: indications, contraindications, technique, and complications.

G Guglielmi1, C Andreula, M Muto, L A Gilula.   

Abstract

Percutaneous vertebroplasty is emerging as one of the most promising new interventional procedures for relieving (or reducing) painful vertebra, with the injection of surgical polymethylmethacrylate or cement into vertebral bodies. This imaged-guided technique, originally used to treat vertebral hemangioma, has recently been extended to the treatment of metastases, osteoporotic compression fractures, and vertebral myeloma. It is increasingly being accepted as a main treatment of choice in the management of resistant back pain due to vertebral compression fractures, especially in the elderly individual who is not a candidate for surgery. In this article, we review indications, contraindications, technique, and complications of percutaneous vertebroplasty.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15981722     DOI: 10.1080/02841850510021049

Source DB:  PubMed          Journal:  Acta Radiol        ISSN: 0284-1851            Impact factor:   1.990


  16 in total

Review 1.  Vertebral fractures in dialysis: Endocrinological disruption of the bone-kidney axis.

Authors:  M Fusaro; A D'Angelo; G Scalzo; M Gallieni; S Giannini; G Guglielmi
Journal:  J Endocrinol Invest       Date:  2010-05       Impact factor: 4.256

2.  Catheter-directed percutaneous transpedicular C2/C3 vertebroplasty in a patient with fibrous dysplasia using seldinger technique.

Authors:  G Christoforidis; D Dang; J Gabriel
Journal:  AJNR Am J Neuroradiol       Date:  2006-09       Impact factor: 3.825

3.  Aggravation of spinal cord compromise following new osteoporotic vertebral compression fracture prevented by teriparatide in patients with surgical contraindications.

Authors:  Y Zhao; R Xue; N Shi; Y Xue; Y Zong; W Lin; B Pei; C Sun; R Fan; Y Jiang
Journal:  Osteoporos Int       Date:  2016-05-31       Impact factor: 4.507

4.  Risk factors of developing new symptomatic vertebral compression fractures after percutaneous vertebroplasty in osteoporotic patients.

Authors:  Wan Soo Lee; Kyeong Hoon Sung; Hyun Tae Jeong; Youn Sang Sung; Yong In Hyun; Jae Young Choi; Kyu Seok Lee; Chul Su Ok; Young Woo Choi
Journal:  Eur Spine J       Date:  2006-07-21       Impact factor: 3.134

5.  Initial clinical experience with a new biointegrative cement for vertebroplasty in osteoporotic vertebral fractures.

Authors:  S Siemund; L T Nilsson; M Cronqvist; B Strömqvist
Journal:  Interv Neuroradiol       Date:  2009-11-04       Impact factor: 1.610

6.  Comparative clinical results of vertebroplasty using jamshidi® needle and bone void filler for acute vertebral compression fractures.

Authors:  Se-Il Jeon; Il-Seung Choe; Young Sub Kwon; Dae-Hee Seo; Kyu Chang Lee; Sung-Choon Park
Journal:  Korean J Spine       Date:  2012-09-30

7.  Percutaneous vertebroplasty at C2: case report of a patient with multiple myeloma and a literature review.

Authors:  Miriam Rodriguez-Catarino; Cecilie Blimark; Jan Willén; Ulf-H Mellqvist; Stig Rödjer
Journal:  Eur Spine J       Date:  2006-12-08       Impact factor: 3.134

8.  CT-guided vertebroplasty: analysis of technical results, extraosseous cement leakages, and complications in 500 procedures.

Authors:  Michael Bernhard Pitton; Sascha Herber; Ulrike Koch; Katja Oberholzer; Philip Drees; Christoph Düber
Journal:  Eur Radiol       Date:  2008-06-04       Impact factor: 5.315

9.  Investigating sacroplasty: technical considerations and finite element analysis of polymethylmethacrylate infusion into cadaveric sacrum.

Authors:  C T Whitlow; S K Yazdani; M L Reedy; S E Kaminsky; J L Berry; P P Morris
Journal:  AJNR Am J Neuroradiol       Date:  2007 Jun-Jul       Impact factor: 3.825

10.  CT-guided vertebroplasty in osteoprotic vertebral fractures: incidence of secondary fractures and impact of intradiscal cement leakages during follow-up.

Authors:  M B Pitton; S Herber; C Bletz; P Drees; N Morgen; U Koch; B Böhm; A Eckardt; C Düber
Journal:  Eur Radiol       Date:  2007-07-19       Impact factor: 5.315

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.